Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.

Phase 1/Phase 2

Novartis Pharmaceuticals

Imatinib Mesylate